PREDICTIVE HEALTH - PROSPECTIVE BIOMARKER ASSESSMENT OF METABOLIC & VASCULAR RIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的总体目的是确定生物标志物分析是否可以预测代谢和血管功能的丧失。该预测性健康项目将利用“SIGT研究”- NIDDK R18 DK-066204（P.I.：L.S.菲利普斯），“IGT（葡萄糖耐量受损）筛查：葡萄糖挑战与预测模型”（09/01/04-08/30/08）。入组SIGT研究的基线葡萄糖耐量正常的患者将进行以下基线和1年评估：（a）氧化应激（GSH：GSSG比值、FORT、硝基酪氨酸和异前列腺素）和（B）炎症介质/生物标志物（hs-CRP、IL-6、5种其他细胞因子），以及（c）颈动脉内膜中层厚度和（d）重复口服葡萄糖耐量试验。 还将对样品进行处理，以便（e）进行随后的蛋白质组学和代谢组学分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall purpose of this study is to determine whether biomarker profiling will predict loss of metabolic and vascular function. This predictive health project will take advantage of the availability of well-characterized subjects from the "SIGT Study" - NIDDK R18 DK-066204 (P.I.: L.S. Phillips), "Screening for IGT (impaired glucose tolerance): Glucose Challenge vs. Predictive Model" (09/01/04-08/30/08). Patients enrolled in the SIGT study, with normal glucose tolerance at baseline, will have baseline and 1-year assessment of (a) oxidative stress (GSH:GSSG ratio, FORT, nitrotyrosine, and isoprostanes) and (b) inflammatory mediators/biomarkers (hs-CRP, IL-6, five other cytokines), together with (c) carotid intima-media thickness and (d) repeat oral glucose tolerance tests. Samples will also be processed to permit (e) subsequent proteomics and metabolomics analyses.